SAN DIEGO–(BUSINESS WIRE)–Setara Biosciences, Inc. (Setara), a clinical-stage biotechnology company leveraging genetics to develop precision medicines for severe rare diseases, today announced the completion of a $90 million Series A financing. Setara was formed following the closing of Jazz Pharmaceuticals’ acquisition of Actio Biosciences (Actio) for its lead program ABS-1230, an investigational therapy for KCNT1-related epilepsy. Setara intends to advance Actio’s remaining pipeline, led by
